Compare Erajaya Swasembada Tbk. (ERAA) vs Tempo Scan Pacific Tbk. (TSPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Erajaya Swasembada Tbk. vs Tempo Scan Pacific Tbk. — how do they compare? Erajaya Swasembada Tbk. trades at Rp595 (market cap 9.41T, 91.64M 24h volume), while Tempo Scan Pacific Tbk. trades at Rp2,730 (market cap 12.36T, 1.41M 24h volume). The key difference: Tempo Scan Pacific Tbk. is the larger of the two by market cap, and Erajaya Swasembada Tbk. is more actively traded (91.64M versus 1.41M). Which is the better fit depends on your goals.
| ERAA | TSPC | |
|---|---|---|
Market Cap | 9.41T | 12.36T |
Volume | 91.64M | 1.41M |
Lot | 916.38K | 14.08K |
Turnover | 53.7B | 3.83B |
Average Price | 585.95 | 2,722.04 |
Value | 53.7B | 3.83B |
Indicative Equilibrium Price | 595 | 2,730 |
Indicative Equilibrium Volume | 32.64K | 2.51K |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Erajaya Swasembada Tbk.
PT Erajaya Swasembada Tbk (the Company) was established in Jakarta based on Notarial Deed No.7 of Myra Yuwono, S.H., dated October 8, 1996. Erajaya Group is the official distributor for 10 international mobile communication brands and an authorised partner for major mobile operators. Recently, the Group has launched its own mobile handset under the name of Venera. In 1996, PT Erajaya Swasembada, or Erajaya, the establishment of what we know today as the Erajaya Group, was incorporated.
Read more on ERAA →About Tempo Scan Pacific Tbk.
PT. Tempo Scan Pacific Tbk (the Company) was established in the Republic of Indonesia dated 20 May 1970, under its original name PT Scanchemie within the framework of the Domestic Capital Investment Law No. 6 year 1968, as amended by Law No. 12 year 1970, based on Notarial Deed No. 37 of Ridwan Suselo, S.H. The company is famous for such pharmaceutical products as Bodrex, Hemaviton and Neo-Rheumacyl.
Read more on TSPC →
